PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9379848-3 1997 Regionally, 32 days treatment with haloperidol (3 mg/kg/day), sulpiride (100 mg/kg/day) or clozapine (10 mg/kg/day) resulted in a drop of approximately 30-40% in 5HT2C mRNA levels in both cortex and cerebellum, and decreases (or non-significant trends) of 15-40% in 5HT2A mRNA levels in hippocampus, brainstem and mid brain. Haloperidol 35-46 5-hydroxytryptamine receptor 2C Rattus norvegicus 162-167 15986194-0 2005 Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. Haloperidol 54-65 5-hydroxytryptamine receptor 2C Rattus norvegicus 9-15 15986194-5 2005 OBJECTIVES: In the present study, we tested the hypothesis that repeated daily administration of haloperidol leads to enhanced serotonin 5-HT2C receptor signaling that is associated with increased 5-HT2C-mediated VCM. Haloperidol 97-108 5-hydroxytryptamine receptor 2C Rattus norvegicus 137-143 15986194-5 2005 OBJECTIVES: In the present study, we tested the hypothesis that repeated daily administration of haloperidol leads to enhanced serotonin 5-HT2C receptor signaling that is associated with increased 5-HT2C-mediated VCM. Haloperidol 97-108 5-hydroxytryptamine receptor 2C Rattus norvegicus 197-203 15986194-13 2005 Striatal 5-HT2C receptor-mediated phospholipase C (PLC) activity and high-affinity agonist-labeled 5-HT2C receptors were also increased following either dose of haloperidol as compared to vehicle treatment. Haloperidol 161-172 5-hydroxytryptamine receptor 2C Rattus norvegicus 9-15 15986194-13 2005 Striatal 5-HT2C receptor-mediated phospholipase C (PLC) activity and high-affinity agonist-labeled 5-HT2C receptors were also increased following either dose of haloperidol as compared to vehicle treatment. Haloperidol 161-172 5-hydroxytryptamine receptor 2C Rattus norvegicus 99-105 15986194-15 2005 CONCLUSIONS: Repeated daily administration of haloperidol leads to an adaptive increase in 5-HT2C signaling which may contribute to abnormal motor function associated with antipsychotic use. Haloperidol 46-57 5-hydroxytryptamine receptor 2C Rattus norvegicus 91-97 15917433-6 2005 Whereas haloperidol, a typical antipsychotic drug that is primarily a dopamine receptor antagonist, reduced 5-HT2C VNV isoform frequency and the level of RNA editing at the D site, risperidone and not the prototype atypical antipsychotic drug clozapine increased the frequency of 5-HT2C VNV and D-site editing. Haloperidol 8-19 5-hydroxytryptamine receptor 2C Rattus norvegicus 108-114 15917433-6 2005 Whereas haloperidol, a typical antipsychotic drug that is primarily a dopamine receptor antagonist, reduced 5-HT2C VNV isoform frequency and the level of RNA editing at the D site, risperidone and not the prototype atypical antipsychotic drug clozapine increased the frequency of 5-HT2C VNV and D-site editing. Haloperidol 8-19 5-hydroxytryptamine receptor 2C Rattus norvegicus 280-286 16182256-1 2006 BACKGROUND: Central serotonin2C (5-HT2C) receptors are known to play a role in the mechanism of action of the antipsychotic drugs (APDs) clozapine and haloperidol. Haloperidol 151-162 5-hydroxytryptamine receptor 2C Rattus norvegicus 33-39 16182256-3 2006 METHODS: Using in vivo microdialysis in halothane-anesthetized rats, we assessed the ability of selective 5-HT2C compounds to modulate the release of DA induced by haloperidol and clozapine in the nucleus accumbens and striatum. Haloperidol 164-175 5-hydroxytryptamine receptor 2C Rattus norvegicus 106-112 16182256-5 2006 The effect of .01 mg/kg haloperidol was potentiated by the 5-HT2C inverse agonist SB 206553 (5 mg/kg) but unaltered by the 5-HT2C antagonists SB 243213 and SB 242084 (1 mg/kg). Haloperidol 24-35 5-hydroxytryptamine receptor 2C Rattus norvegicus 59-65 16182256-7 2006 CONCLUSIONS: These results show that clozapine and haloperidol differentially alter the constitutive activity of 5-HT2C receptors and suggest that clozapine behaves as a 5-HT2C inverse agonist in vivo. Haloperidol 51-62 5-hydroxytryptamine receptor 2C Rattus norvegicus 113-119 16182256-7 2006 CONCLUSIONS: These results show that clozapine and haloperidol differentially alter the constitutive activity of 5-HT2C receptors and suggest that clozapine behaves as a 5-HT2C inverse agonist in vivo. Haloperidol 51-62 5-hydroxytryptamine receptor 2C Rattus norvegicus 170-176 1496128-2 1992 The effects of chronic treatment with the atypical antipsychotic, clozapine, and classical antipsychotic, haloperidol, on serotonergic 5-HT-1c and dopamine D2 receptors in rat brain were studied with radioligand binding methods. Haloperidol 106-117 5-hydroxytryptamine receptor 2C Rattus norvegicus 135-142 7898773-5 1994 5-HT2C receptors: clozapine (7.19) > chlorpromazine > risperidone > thioridazine > fluphenazine > spiperone > haloperidol (< 4.00). Haloperidol 128-139 5-hydroxytryptamine receptor 2C Rattus norvegicus 0-6 7851496-1 1994 We studied the effects of acute clozapine and haloperidol treatments on 5-HT2C receptor binding characteristics and 5-HT2C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus. Haloperidol 46-57 5-hydroxytryptamine receptor 2C Rattus norvegicus 72-78 8386235-5 1993 The 5-HT1C/2 receptor agonist 2,5-dimethoxy-4-bromoamphetamine also completely reversed HAL-induced catalepsy, an effect blocked by ketanserin, but not pindolol. Haloperidol 88-91 5-hydroxytryptamine receptor 2C Rattus norvegicus 4-10